Asked by: Bambos Charalambous (Labour - Southgate and Wood Green)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps the Department is taking to improve early identification and monitoring of precursor conditions for blood cancer, such as MGUS and smoldering myeloma.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
It is a priority for the Government to support the National Health Service to diagnose blood cancer and precursor conditions as quickly as possible and to treat them faster, to improve outcomes.
To improve diagnoses of blood cancers and precursor conditions, the NHS is implementing non-specific symptom (NSS) pathways for patients who present with symptoms such as weight loss and fatigue, which do not clearly align to a tumour type. Blood cancers are one of the most common cancer types diagnosed through these pathways. There are currently 115 NSS services operating in England, ensuring more patients benefit from quicker access to the right investigations.
The Government will get the NHS diagnosing blood cancers earlier and treating them faster, and will support the NHS to increase capacity to meet the demand for diagnostic services through investment, including for magnetic resonance imaging and computed tomography scanners.
The National Cancer Plan, which will be published in the new year, will include further details on how the NHS will improve outcomes for all cancer patients, including speeding up diagnosis and treatment, ensuring patients have access to the latest treatments and technology, and ultimately driving up this country’s cancer survival rates.
Asked by: Bambos Charalambous (Labour - Southgate and Wood Green)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether he plans to introduce a data-driven system to (a) identify and (b) address disparities in the early diagnosis of cancer.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department remains committed to making improvements across different cancer types and to reducing disparities in cancer survival. Early cancer diagnosis is also a specific priority within the National Health Service’s wider Core20Plus5 approach to reducing healthcare inequalities.
The National Disease Registration Service (NDRS) in NHS England is the cancer registry for England and collects data on the diagnosis and treatment of cancer patients. The data collected captures a patient’s complete journey from referral, diagnosis, treatment, outcomes, experience, and survival. The data collected is used to inform trends and monitor and detect changes in health and disease in the population, including disparities in diagnosis. NDRS’s strategic priorities focus on making data more timely and accessible, and better understanding health inequalities.
Furthermore, the National Cancer Plan, to be published in the new year, will include further details on how we will use data to improve outcomes for cancer patients in England, including by driving earlier diagnosis and reducing the gap in early diagnosis between those living in the richest and poorest areas.
Asked by: Bambos Charalambous (Labour - Southgate and Wood Green)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether his Department plans to increase research funding into new (a) tools and (b) other technologies for the earlier diagnosis of (i) pancreatic, (ii) lung, (iii) liver, (iv) stomach, (v) brain, (vi) oesophageal cancers and (vii) other the less survivable cancers.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department invests over £1.6 billion each year on research through its research delivery arm, the National Institute for Health and Care Research (NIHR).
An example of this is the NIHR investing £2.4 million into the miONCO-Dx trial, which seeks to develop a blood test designed to detect 12 different cancers, that could transform how cancer is diagnosed in the National Health Service.
The NIHR is also funding a new artificial intelligence (AI) powered radiology analysis service, designed to develop and evaluate the use of AI in medical imaging to improve the detection of cancers, including for lung and brain tumours. The use of this technology will help to speed up response times and provide more accurate diagnoses and better-targeted treatments, ultimately improving outcomes for patients.
The NIHR continues to welcome funding applications for research into any aspect of human health and care, including all cancers. These applications are subject to peer review and judged in open competition, with awards being made on the basis of the importance of the topic to patients and health and care services, value for money, and scientific quality.
Asked by: Bambos Charalambous (Labour - Southgate and Wood Green)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to improve access to innovative treatments for people with SOD1 motor neurone disease.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
The National Institute for Health and Care Excellence (NICE) is the independent body responsible for developing authoritative, evidence-based recommendations for the Naitonal Health Service on whether new medicines represent a clinically and cost-effective use of resources. NICE aims, wherever possible, to issue guidance close to the time of licensing, and the NHS in England is legally required to fund medicines recommended by NICE, normally within three months of the publication of final guidance.
NICE has selected tofersen for treating amyotrophic lateral sclerosis caused by SOD1 gene mutations as a topic for guidance development through its Highly Specialised Technology (HST) programme. The HST programme appraises medicines for the treatment of very rare, and often very severe diseases, and evaluates whether they can be considered a clinically and cost-effective use of NHS resources. NICE is working with the company to confirm timelines for this evaluation.
Asked by: Bambos Charalambous (Labour - Southgate and Wood Green)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment his Department has made of (a) the distances travelled and (b) costs incurred by children and young people travelling to principle treatment centres in London; and what assessment he has made of the potential the merits of introducing a young cancer patient travel fund.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department of Health and Social Care knows that the cost of travel is an important issue for many young cancer patients and their families in England. NHS England and the integrated care boards are responsible for commissioning and ensuring the healthcare needs of their local communities are met, including providing support for travel.
The National Health Service in England runs the Healthcare Travel Costs Scheme (HTCS) to provide financial assistance for travel to a hospital or other NHS premises for specialist NHS treatment or diagnostics tests, when referred by a doctor or other primary healthcare professional. Patients who do not qualify for the HTCS and who are on a low income may be able to claim the costs from the Department for Work and Pensions through Universal Credit or a Personal Independence Payment. There are also several charities in the United Kingdom who provide support, including financial support, for patients with cancer.
On 4 February 2025, the Department of Health and Social Care relaunched the Children and Young People Cancer Taskforce to identify tangible ways to improve outcomes and experiences for young cancer patients. The work of the taskforce is ongoing, and officials are exploring opportunities for improvement across a range of areas, including detection and diagnosis, genomic testing and treatment, research and innovation, and patient experience. The taskforce will also ensure that the unique needs of children and young people with cancer are carefully considered as part of the National Cancer Plan, which will include further details on how we will improve outcomes for children and young people with cancer in England.
The Department of Health and Social Care has not made a formal assessment of costs incurred by children and young people travelling to Principal Treatment Centres in London, the trends in levels of travel costs and the impact of this on young cancer patients missing appointments and delaying treatment. Young Lives vs Cancer is a valued stakeholder with a unique perspective on the issue of travel support for children and young people with cancer. The Department of Health and Social Care will continue to engage with Young Lives vs Cancer, as well as other children and young people cancer charity stakeholders as we progress this important work.
Asked by: Bambos Charalambous (Labour - Southgate and Wood Green)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, with reference to Young Lives vs Cancer's report entitled A young cancer patient travel fund, published in February 2024, whether his Department has made an assessment of (a) trends in levels of travel costs, (b) the adequacy of the amount of financial support for young cancer patients and their families and (b) the potential impact on (i) missing appointments and (ii) delaying treatment.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department of Health and Social Care knows that the cost of travel is an important issue for many young cancer patients and their families in England. NHS England and the integrated care boards are responsible for commissioning and ensuring the healthcare needs of their local communities are met, including providing support for travel.
The National Health Service in England runs the Healthcare Travel Costs Scheme (HTCS) to provide financial assistance for travel to a hospital or other NHS premises for specialist NHS treatment or diagnostics tests, when referred by a doctor or other primary healthcare professional. Patients who do not qualify for the HTCS and who are on a low income may be able to claim the costs from the Department for Work and Pensions through Universal Credit or a Personal Independence Payment. There are also several charities in the United Kingdom who provide support, including financial support, for patients with cancer.
On 4 February 2025, the Department of Health and Social Care relaunched the Children and Young People Cancer Taskforce to identify tangible ways to improve outcomes and experiences for young cancer patients. The work of the taskforce is ongoing, and officials are exploring opportunities for improvement across a range of areas, including detection and diagnosis, genomic testing and treatment, research and innovation, and patient experience. The taskforce will also ensure that the unique needs of children and young people with cancer are carefully considered as part of the National Cancer Plan, which will include further details on how we will improve outcomes for children and young people with cancer in England.
The Department of Health and Social Care has not made a formal assessment of costs incurred by children and young people travelling to Principal Treatment Centres in London, the trends in levels of travel costs and the impact of this on young cancer patients missing appointments and delaying treatment. Young Lives vs Cancer is a valued stakeholder with a unique perspective on the issue of travel support for children and young people with cancer. The Department of Health and Social Care will continue to engage with Young Lives vs Cancer, as well as other children and young people cancer charity stakeholders as we progress this important work.
Asked by: Bambos Charalambous (Labour - Southgate and Wood Green)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to tackle inequalities in (a) access to clinical trials and (b) specialist psychological support for young people with cancer.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department is committed to maximising the United Kingdom’s potential to lead the world in clinical research and to ensuring that clinical trials are more accessible.
The Department funded National Institute for Health and Care Research (NIHR) funds research and research infrastructure, which supports patients and the public to participate in high-quality research, including clinical trial participation for young people with cancer.
The NIHR has made research inclusion a condition of its funding. Applicants to domestic research programmes are required to demonstrate how inclusion is being built into all stages of the research lifecycle, and are also required to provide details of how their research contributes towards the NIHR’s mission to reduce health and care inequalities. Before the end of March 2026, this will also be required for global health research and infrastructure awards.
The Department is dedicated to ensuring that all children and young people with cancer have access to psychological support, to help them through their diagnosis and treatment.
NHS England has published service specifications that set out the service standards required of all providers of children and young people’s cancer services. The requirements include ensuring that every patient has access to specialist care and reducing physical, emotional, and psychological morbidity arising from the treatment for childhood cancer. Further information on NHS England’s published service specifications is available at the following link:
https://www.england.nhs.uk/commissioning/spec-services/npc-crg/group-b/b05/
Children and young people’s cancer care is managed by Principal Treatment Centres (PTCs) who ensure quality care. Each PTC has a multi-disciplinary team which meets at least weekly and includes a specific focus on the psychosocial needs of patients. The multi-disciplinary team ensures that each service user is assessed for psychological needs and can access any psychosocial support that is required.
Asked by: Bambos Charalambous (Labour - Southgate and Wood Green)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking within current NHS workforce planning to improve uptake of digital consultations for Parkinson’s patients as a mechanism to reduce neurology waiting times and reduce the backlog in accessing a neurologist.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
We have delivered an additional two million appointments, seven months ahead of schedule. This includes operations, consultations, diagnostic tests, and treatments. These additional appointments have taken place across a number of specialities, including neurology.
Whilst no specific assessment has been made of how workforce shortages are impacting the delivery of care, there are a number of initiatives supporting service improvement and better care for patients with Parkinson’s disease in England, including the Getting It Right First Time Programme for Neurology, the RightCare Progressive Neurological Conditions Toolkit, and the Neurology Transformation Programme.
We have launched a 10-Year Health Plan to reform the National Health Service. The plan will set out a bold agenda to deliver on the three big shifts needed, to move healthcare from hospital to the community, from analogue to digital, and from treatment to prevention.
A central and core part of the 10-Year Health Plan will be our workforce and how we ensure we train and provide the staff, technology, and infrastructure the NHS needs to care for patients across our communities.
Asked by: Bambos Charalambous (Labour - Southgate and Wood Green)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to (a) help tackle shortages across the Parkinson’s disease specialist workforce and (b) assess how current workforce shortages are impacting the delivery of multi-disciplinary care as outlined in NICE guidance; and what plans he has to increase the Parkinson’s disease specialists workforce.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
We have delivered an additional two million appointments, seven months ahead of schedule. This includes operations, consultations, diagnostic tests, and treatments. These additional appointments have taken place across a number of specialities, including neurology.
Whilst no specific assessment has been made of how workforce shortages are impacting the delivery of care, there are a number of initiatives supporting service improvement and better care for patients with Parkinson’s disease in England, including the Getting It Right First Time Programme for Neurology, the RightCare Progressive Neurological Conditions Toolkit, and the Neurology Transformation Programme.
We have launched a 10-Year Health Plan to reform the National Health Service. The plan will set out a bold agenda to deliver on the three big shifts needed, to move healthcare from hospital to the community, from analogue to digital, and from treatment to prevention.
A central and core part of the 10-Year Health Plan will be our workforce and how we ensure we train and provide the staff, technology, and infrastructure the NHS needs to care for patients across our communities.
Asked by: Bambos Charalambous (Labour - Southgate and Wood Green)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to help reduce variations in access to treatments approved by the National Institute for Health and Care Excellence for advanced and complex Parkinson’s Disease.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
We have delivered an additional two million appointments in England, seven months ahead of schedule. This includes operations, consultations, diagnostic tests, and treatments. These additional appointments have taken place across a number of specialities, including neurology.
We have launched a 10-Year Health Plan to reform the National Health Service. The plan will set out a bold agenda to deliver on the three big shifts needed, to move healthcare from hospital to the community, from analogue to digital, and from treatment to prevention. A central and core part of the 10-Year Health Plan will be our workforce and how we ensure we train and provide the staff, technology, and infrastructure the NHS needs to care for patients, including for those with Parkinson’s, across our communities.
There are a number of initiatives supporting service improvement and better care for patients with Parkinson’s disease in England, including the Getting It Right First Time (GIRFT) Programme for Neurology, the RightCare Progressive Neurological Conditions Toolkit, and the Neurology Transformation Programme (NTP).
The GIRFT National Specialty Report made recommendations designed to improve services nationally and to support the NHS to deliver care more equitably across the country. The report highlighted differences in how services are delivered, and provided the opportunity to share successful initiatives between trusts to improve patient services nationally. In addition, the NTP has developed a model of integrated care for neurology services to support integrated care boards (ICBs) to deliver the right service, at the right time for all neurology patients, which includes providing care closer to home.
Once diagnosed, and with a management strategy in place, the majority of people with Parkinson’s can be cared for through routine access to primary and secondary care. NHS England commissions the specialised elements of Parkinson’s care that patients may receive from 27 neurology centres across England. Within these specialised centres, neurological multidisciplinary teams ensure patients can access a range of health professionals, including Parkinson’s disease nurses, psychologists, and allied health professionals such as dieticians and speech and language therapists, and that they can receive specialised treatment and support, according to their needs.
In addition, in February 2024, a new treatment for advanced-stage Parkinson’s, foslevodopa–foscarbidopa, was rolled out in the NHS. It has been shown to improve motor function, with patients experiencing longer periods of time without dyskinesia.
The NHS in England is legally required to make funding available for treatments recommended in National Institute for Health and Care Excellence (NICE) technology appraisal guidance. If there are any concerns with the availability of a NICE-recommended treatment in a particular area, they should be raised with the local ICB in the first instance.